Ewa Poduch
University of Toronto
Network
Latest external collaboration on country level. Dive into details by clicking on the dots.
Publication
Featured researches published by Ewa Poduch.
Journal of Biological Chemistry | 2008
Jian Payandeh; Canhui Li; Mohabir Ramjeesingh; Ewa Poduch; Christine E. Bear; Emil F. Pai
Recent crystal structures of the CorA Mg2+ transport protein from Thermotoga maritima (TmCorA) revealed an unusually long ion pore putatively gated by hydrophobic residues near the intracellular end and by universally conserved asparagine residues at the periplasmic entrance. A conformational change observed in an isolated funnel domain structure also led to a proposal for the structural basis of gating. Because understanding the molecular mechanisms underlying ion channel and transporter gating remains an important challenge, we have undertaken a structure-guided engineering approach to probe structure-function relationships in TmCorA. The intracellular funnel domain is shown to constitute an allosteric regulatory module that can be engineered to promote an activated or closed state. A periplasmic gate centered about a proline-induced kink of the pore-lining helix is described where “helix-straightening” mutations produce a dramatic gain-of-function. Mutation to the narrowest constriction along the pore demonstrates that a hydrophobic gate is operational within this Mg2+-selective transport protein and likely forms an energetic barrier to ion flux. We also provide evidence that highly conserved acidic residues found in the short periplasmic loop are not essential for TmCorA function or Mg2+ selectivity but may be required for proper protein folding and stability. This work extends our gating model for the CorA-Alr1-Mrs2 superfamily and reveals features that are characteristic of an ion channel. Aspects of these results that have broader implications for a range of channel and transporter families are highlighted.
Journal of Medicinal Chemistry | 2009
Angelica M. Bello; Danijela Konforte; Ewa Poduch; Caren Furlonger; Lianhu Wei; Yan Liu; Melissa Maureen Lewis; Emil F. Pai; Christopher J. Paige; Lakshmi P. Kotra
A series of 6-substituted and 5-fluoro-6-substituted uridine derivatives were synthesized and evaluated for their potential as anticancer agents. The designed molecules were synthesized from either fully protected uridine or the corresponding 5-fluorouridine derivatives. The mononucleotide derivatives were used for enzyme inhibition investigations against ODCase. Anticancer activities of all the synthesized derivatives were evaluated using the nucleoside forms of the inhibitors. 5-Fluoro-UMP was a very weak inhibitor of ODCase. 6-Azido-5-fluoro and 5-fluoro-6-iodo derivatives are covalent inhibitors of ODCase, and the active site Lys145 residue covalently binds to the ligand after the elimination of the 6-substitution. Among the synthesized nucleoside derivatives, 6-azido-5-fluoro, 6-amino-5-fluoro, and 6-carbaldehyde-5-fluoro derivatives showed potent anticancer activities in cell-based assays against various leukemia cell lines. On the basis of the overall profile, 6-azido-5-fluoro and 6-amino-5-fluoro uridine derivatives exhibited potential for further investigations.
Journal of Medicinal Chemistry | 2008
Ewa Poduch; Lianhu Wei; Emil F. Pai; Lakshmi P. Kotra
Orotidine monophosphate decarboxylase (ODCase) generally accepts pyrimidine-based mononucleotides as ligands, but other nucleotides are also known to bind to this enzyme. We investigated the kinetic properties of eight common and endogenous nucleotides with ODCases from three species: Methanobacterium thermoautotrophicum, Plasmodium falciparum, and Homo sapiens. UMP and XMP exhibited higher affinities as compared to the other nucleotides tested. The product of ODCase catalyzed decarboxylation, UMP, displayed inhibition constants (K(i)) of 330 microM against the Mt enzyme and of 210 and 220 microM against the Pf and Hs ODCases, respectively. The K(i) values for XMP were 130 microM and 43 microM, respectively, for Mt and Pf ODCases. Interestingly, XMPs affinity for human ODCase (K(i) = 0.71 microM) is comparable and even slightly better than that of the substrate OMP. Binding of various nucleotides and their structural features in the context of ODCase inhibition and inhibitor design are discussed.
Journal of Medicinal Chemistry | 2007
Angelica M. Bello; Ewa Poduch; Masahiro Fujihashi; Merhnaz Amani; Yan Li; Ian Crandall; Raymond Hui; Ping I. Lee; Kevin C. Kain; Emil F. Pai; Lakshmi P. Kotra
Journal of Medicinal Chemistry | 2006
Ewa Poduch; Angelica M. Bello; Sishi Tang; Masahiro Fujihashi; Emil F. Pai; Lakshmi P. Kotra
Journal of Medicinal Chemistry | 2008
Angelica M. Bello; Ewa Poduch; Yan Liu; Lianhu Wei; Ian Crandall; Xiaoyang Wang; Christopher Dyanand; Kevin C. Kain; Emil F. Pai; Lakshmi P. Kotra
Journal of the American Chemical Society | 2005
Masahiro Fujihashi; Angelica M. Bello; Ewa Poduch; Lianhu Wei; Subhash C. Annedi; Emil F. Pai; Lakshmi P. Kotra
Mini-reviews in Medicinal Chemistry | 2008
Lakshmi P. Kotra; Maria Elena Meza-Aviña; Lianhu Wei; M. G. Buhendwa; Ewa Poduch; Angelica M. Bello; Emil F. Pai
Bioorganic & Medicinal Chemistry | 2006
Subhash C. Annedi; Farooq Biabani; Ewa Poduch; Baskar M. Mannargudi; Kanchana Majumder; Lianhu Wei; Reza Khayat; Liang Tong; Lakshmi P. Kotra
Journal of Medicinal Chemistry | 2011
Melissa Maureen Lewis; Maria Elena Meza-Aviña; Lianhu Wei; Ian Crandall; Angelica M. Bello; Ewa Poduch; Yan Liu; Christopher J. Paige; Kevin C. Kain; Emil F. Pai; Lakshmi P. Kotra